Voyager Therapeutics, Inc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Voyager Therapeutics, Inc
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Eight $1bn+ alliances were penned in January. Topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases.
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Third Rock Ventures, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.